Actively Recruiting
Evaluating AI Software for Early Detection of Diabetic Retinopathy Using Fundus Photography in Adults with Diabetes
Led by The Filatov Institute of Eye Diseases and Tissue Therapy · Updated on 2025-03-17
200
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating an artificial intelligence AI software platform called Retina-AI to detect diabetic retinopathy DR, a complication of diabetes that affects the eyes. The study includes adults aged 18 to 90 who have diabetes mellitus or risk factors for developing diabetes. The goal is to assess the accuracy of this AI tool in identifying DR from eye images. During the study, participants will have fundus photos taken of their eyes using a non-mydriatic fundus camera, which does not require pupil dilation. Two images per eye are capturedone centered on the optic disc and one on the fovea. These images are then uploaded into the AI system, where a neural network processes them to detect signs of diabetic retinopathy. Participants will undergo imaging at the start of the study to provide baseline data. Researchers will measure the accuracy of the AI in detecting DR, including the percentage of invalid images and false positive results. The study is observational and involves no drug treatments. Participants data will be collected and analyzed to evaluate the AIs performance in screening for diabetic retinopathy.
CONDITIONS
Brief Title
Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening
Research Team
A
Andrii MD Korol, PhD
O
Olha MD Pohosian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
